| |
| |
| List of principal contributors | |
| |
| |
| List of chairpersons | |
| |
| |
| Preface | |
| |
| |
| |
| Advances in the Pathogenesis of Inflammatory Bowel Disease | |
| |
| |
| |
| |
| Innate immune responses in inflammatory bowel disease | |
| |
| |
| |
| |
| The adaptive immune responses in inflammatory bowel disease | |
| |
| |
| |
| |
| Relevance of bacteria in the pathogenesis of inflammatory bowel disease | |
| |
| |
| |
| |
| Taking a toll on MD-2 in inflammatory bowel disease | |
| |
| |
| |
| |
| Optimization in Therapy through Improved Disease Classification? | |
| |
| |
| |
| |
| Classification of inflammatory bowel disease can only be based on the clinical phenotype | |
| |
| |
| |
| |
| Use of serology and genetics to differentiate inflammatory bowel disease phenotypes | |
| |
| |
| |
| |
| Do biomarkers help to optimize therapy in inflammatory bowel disease? | |
| |
| |
| |
| |
| Role of pharmacogenetics in the management of inflammatory bowel diseases | |
| |
| |
| |
| |
| Conventional Immunomodulator Therapy | |
| |
| |
| |
| |
| State-of-the-art therapy in accordance with guidelines | |
| |
| |
| |
| |
| Increased risk of morbidity associated with immunomodulatory treatment in patients with inflammatory bowel diseases | |
| |
| |
| |
| |
| Can immunomodulatory therapy be improved by metabolite measurement and combination therapy? | |
| |
| |
| |
| |
| Relevance of Biologics | |
| |
| |
| |
| |
| Top-down therapy for inflammatory bowel disease | |
| |
| |
| |
| |
| 'Step-up' versus 'top-down' strategies in inflammatory bowel disease - what do we know in 2006? | |
| |
| |
| |
| |
| Importance of mucosal healing in Crohn's disease and ulcerative colitis | |
| |
| |
| |
| |
| State-of-the-Art Lecture: Distinct antibacterial-defensin deficiencies in small intestinal and colonic Crohn's disease | |
| |
| |
| |
| |
| New Therapeutic Approaches (Part I) | |
| |
| |
| |
| |
| Oligonucleotides - new therapeutic approaches | |
| |
| |
| |
| |
| Probiotics in inflammatory bowel disease | |
| |
| |
| |
| |
| Helminth ova therapy for inflammatory bowel disease | |
| |
| |
| |
| |
| Retarded release phosphatidylcholine: a new therapeutic option for ulcerative colitis | |
| |
| |
| |
| |
| Topical steroids - rectal application | |
| |
| |
| |
| |
| New Therapeutic Approaches (Part II) | |
| |
| |
| |
| |
| Apheresis | |
| |
| |
| |
| |
| The evolving understanding and therapy of Crohn's disease: innate immunity and sargramostim (GM-CSF) | |
| |
| |
| |
| |
| Immunosuppression with tacrolimus, everolimus and sirolimus | |
| |
| |
| |
| |
| T-cell modulating antibodies in inflammatory bowel disease | |
| |
| |
| |
| Index | |